Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,105 questions in 84 reviews · Metabolic and Endocrine Disorders
current versionsNo studies 434 · 39.3%Ungraded 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR All‐cause mortality · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient satisfaction · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects 12 to 13 weeks · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Weight loss (change in kg) · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | 6 studies · 532 participants | Moderate |
Intervention NR Costs · overweight or obese adults Green tea for weight loss and weight maintenance in overweight or obese adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Functional outcomes · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events (all adverse events) · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | RR 1.06 [0.97, 1.15] | 6 studies · 1450 participants | Very low |
Intervention NR HbA1c change from baseline to end point (%) ( · patients with type 2 diabetes mellitus Colesevelam for type 2 diabetes mellitus (2012) · Cochrane | no estimate extracted | 5 studies · 1315 participants | Very low |
Intervention NR Development of diabetic complications · patients with LADA Interventions for latent autoimmune diabetes (LADA) in adults (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · patients with LADA Interventions for latent autoimmune diabetes (LADA) in adults (2011) · Cochrane | no estimate extracted | 5 studies · 5 participants | Ungraded |
Intervention NR Health‐related quality of life · patients with LADA Interventions for latent autoimmune diabetes (LADA) in adults (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death from any cause · patients with LADA Interventions for latent autoimmune diabetes (LADA) in adults (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health service utilisation and costs · patients with LADA Interventions for latent autoimmune diabetes (LADA) in adults (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR HbA1c at study endpoint · patients with LADA Interventions for latent autoimmune diabetes (LADA) in adults (2011) · Cochrane | no estimate extracted | 4 studies · 160 participants | Low |
Insulin detemir (intervention) vs Insulin glargin (control) Mortality ‐ not reported · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | no estimate extracted | NR | No studies |
Insulin detemir (intervention) vs Insulin glargin (control) Quality of life and treatment satisfaction ‐ not reported · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | no estimate extracted | NR | No studies |
Insulin detemir (intervention) vs Insulin glargin (control) Change in HbA1c · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | no estimate extracted | 4 studies · 2250 participants | Low |
Insulin detemir (intervention) vs Insulin glargin (control) Percentage of participants having at least one severe hypoglycaemic event · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | RR 0.82 [0.51, 1.32] | 4 studies · 2252 participants | Low |
Insulin detemir (intervention) vs Insulin glargin (control) Percentage of participants having at least one hypoglycaemic event · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | RR 0.98 [0.92, 1.05] | 4 studies · 2252 participants | Low |
Insulin detemir (intervention) vs Insulin glargin (control) Weight gain · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | no estimate extracted | 4 studies · 2250 participants | High |
Insulin detemir (intervention) vs Insulin glargin (control) Percentage of participants having at least one injection site reaction · patients with type 2 diabetes mellitus Insulin detemir versus insulin glargine for type 2 diabetes mellitus (2011) · Cochrane | RR 3.31 [1.13, 9.73] | 4 studies · 2252 participants | Low |
Xuezhikang vs simvastatin Cardiovascular events ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin Health‐related quality of life ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin Serious adverse events · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 0 studies · 312 participants | Ungraded |
Xuezhikang vs pravastatin Health costs · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin LDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 3 studies · 307 participants | Low |
Xuezhikang vs pravastatin HDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 3 studies · 307 participants | Low |
Xuezhikang vs simvastatin Death from any cause ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin Health‐related quality of life ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin Serious adverse events · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 0 studies · 703 participants | Ungraded |
Xuezhikang vs simvastatin Health costs ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs simvastatin LDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 10 studies · 885 participants | Very low |
Xuezhikang vs simvastatin HDL‐cholesterol · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | 9 studies · 805 participants | Very low |
Xuezhikang vs pravastatin Cardiovascular events ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Xuezhikang vs pravastatin Death from any cause ‐ not reported · patients with hypercholesterolemia Chinese herbal medicines for hypercholesterolemia (2011) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in HbA1c from baseline to endpoint % ( · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | 14 studies · 6308 participants | High |
Intervention NR Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus another single hypoglycaemic agent % ( · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | 3 studies · 1764 participants | High |
Intervention NR Change in HbA1c from baseline to endpoint ‐ Vildagliptin versus placebo % ( · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | 6 studies · 1139 participants | High |
Intervention NR Change in body weight from baseline to endpoint ‐ Vildagliptin versus placebo kg ( · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | 3 studies · 484 participants | High |
Intervention NR Adverse events ‐ All‐cause infections ( · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | RR 1.04 [0.87, 1.24] | 10 studies · 3573 participants | High |
Intervention NR Health‐related quality of life · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in HbA1c from baseline to endpoint % ( · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | 11 studies · 6907 participants | High |
Intervention NR Change in HbA1c from baseline to endpoint ‐ Sitagliptin versus another single hypoglycaemic agent % ( · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane | no estimate extracted | 2 studies · 592 participants | High |